Search - tctmd.com

Displaying 921 - 940 of 1588

Sort: Relevancy | Date

Presentation TCT 2017

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

Presenter: David P. Faxon, Joseph A. Hill, Ziad A. Ali

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Gregg W. Stone

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Stephen G. Ellis

October 31, 2017

Presentation TCT 2017

Featured Lecture: The NIH Mission to Enhance DIVERSITY in Clinical Trials, Education, and the Workforce

Presenter: Roxana Mehran, George A. Mensah

October 31, 2017

Presentation TCT 2017

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones

October 30, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

Presentation TCT 2017

Risk Score Development, Validation, Precision, Discrimination, and Utility

Presenter: Robert A. Harrington, Sanjay Kaul, Davide Capodanno

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2017

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Presenter: Robert A. Harrington, Sanjay Kaul, Giuseppe Biondi-Zoccai

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Presenter: Robert A. Harrington, Sanjay Kaul

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

Presentation TCT 2017

Vessix RE-INFORCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Michael A. Weber

October 30, 2017

Presentation TCT 2017

MiStent and DESSOLVE III Outcomes: Are the Stent and Clinical Trial Results Unique?

Presenter: Ioannis Iakovou, Gert Richardt, Robert J. de Winter

October 30, 2017

Advertisement

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Live From Denver: TCT 2017, Day Two

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Featured Lecture: The NIH Mission to Enhance DIVERSITY in Clinical Trials, Education, and the Workforce

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Risk Score Development, Validation, Precision, Discrimination, and Utility

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

The PARTNER 3 Low-risk Trial

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Vessix RE-INFORCE Trial Update

MiStent and DESSOLVE III Outcomes: Are the Stent and Clinical Trial Results Unique?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content